Different bleeding risk in type 2A and 2M von Willebrand disease: A 2-year prospective study in 107 patients: A rebuttal

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1455-1458

  Favaloro, E J ^a   Bonar, R ^b   Marsden, K ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b Haematology Quality Assurance Program (QAP)   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HEALTH CARE QUALITY; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LETTER; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE ADHESION; TYPE 2A VON WILLEBRAND DISEASE; TYPE 2M VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE;

FEMALE; HEMORRHAGE; HUMANS; MALE; VON WILLEBRAND DISEASE, TYPE 2;

EID: 84863422161     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04781.x     Document Type: Letter

References (10)

1. Castaman G, Federici AB, Tosetto A, La Marca S, Stufano F, Mannucci PM, Rodeghiero F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10: 632-8.
2. Favaloro EJ. von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37: 440-55.
3. Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, Street A, Marsden K, on behalf of the RCPA QAP in Haematology. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006; 32: 505-13.
4. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al., the Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
5. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-91.
6. Chandler WL, Peerschke EI, Castellone DD, Meijer P; NASCOLA Proficiency Testing Committee. von Willebrand factor assay proficiency testing. The North American specialized coagulation laboratory association experience. Am J Clin Pathol 2011; 135: 862-9.
7. Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of VWF 'activity' assays to large and small molecular weight forms. J Thromb Haemost 2012; 10: 1043-54.
8. Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009; 123: 862-8.
9. Favaloro EJ, Forsyth C, Koutts J. Distinguishing types 1 and 2M von Willebrand disease. Int J Lab Hematol 2012; 34: 102-5.
10. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006; 4: 2088-90.